Therapies for Depressive and Anxiety Disorders

Published - Feb 2010| Analyst - Mary Anne Crandall| Code - PHM056A
Market Research Report Single User License: $2750 Member Price: FREE

Report Highlights

  • The global market for therapies for depressive and anxiety disorders was $28 billion in 2008. It increased to $29.4 billion in 2009. This is projected to reach  $38.5 billion in 2014 at a compound annual growth rate (CAGR) of 5.6%
  • Sales in antidepressants products were nearly $15.4 billion in 2008. It increased to $16.2 billion in 2009. This market is projected to reach $21.2 billion in 2014, for a 5-year CAGR of 5.5%.
  • Sales in antianxiety drugs were nearly $12.6 billion in 2008. It increased to $13.2 billion in 2009. This market is projected to reach $17.3 billion in 2014, for a 5-year CAGR of 5.6%.

INTRODUCTION

STUDY GOALS AND OBJECTIVES 

The objectives of the study are to present a comprehensive look at disorders that affect the mind, specifically that cause depression and anxiety. An overall discussion of mental disorders associated with depression and anxiety is presented along with an in-depth discovery of the various diseases and disorders that present significant problems for individuals and society. Markets are divided according to drug type because several products are used in many different disorders. 

REASONS FOR STUDY
 
This BBC study is presented to highlight the exciting area of mental health, specifically relating to depression and anxiety. Because in-depth study of the workings of the brain is a fairly new area of intense study, there are new and changing theories. The discovery of new mechanisms and chemicals in the brain has provided additional avenues for research and development of products that may alter the course of the diseases or modify the outcome. This study analyzes the current therapies for depression and anxiety and explores the new therapies that are in the pipeline to treat depression and anxiety. The study also addresses the many and varied issues and trends affecting the market. Because of the rapidly evolving climate of psychological disorders and the increasing knowledge of the workings of the brain, manufacturers of therapies for depressive and anxiety disorders must remain ever vigilant of the changing environment and strive to keep abreast of current and potential opportunities.
 
SCOPE OF STUDY
 
The report is designed to be a comprehensive business tool to provide an in-depth look at therapies for depression and anxiety. The geographic scope of the report is global with an emphasis on the United States. The report identifies the different disorders that manifest with depressive and anxiety symptoms; gives an explanation of the disorders; cites incidence; identifies specific drug types; presents current treatments, market size, and market participants; and presents potential treatments in research and development.
 
The market for therapies for depressive and anxiety disorders is divided into two areas:
  • Therapies for depression
  • Therapies for anxiety.
All markets are further broken down into specific types of products that are discussed in detail, measuring current and potential market size; identifying current and potential market drivers; detailing from 2006, 2007, 2008, 2009, and 2014; assessing current and potential competitors; and identifying current competitor market shares.
 
METHODOLOGY AND INFORMATION SOURCES
 
The information and analysis presented in this BCC report are based on extensive first-hand interviews with primary executives, product managers, clinical specialists, and doctors involved in mental health and psychotherapeutics. Industry experts’ perspectives as well as company reports were used in the market analysis. Background information was obtained from various government, business, medical journal, and trade magazines. Key information from published literature was used to conduct interviews with more than 21 industry participants to validate and obtain expert opinions on current and future trends. Interviews were also used to confirm and/or adjust market size and market share estimates as well as formulating market projections. 
 
ANALYST CREDENTIALS
 
Mary Anne Crandall is a Medical Analyst specializing in the pharmaceutical industry for the last 18 years. She has completed several in-depth studies on various medical topics requiring both great medical expertise and excellent knowledge of the industry. Mary Anne has an M.S. in psychology and is pursuing a PhD in education.
 
BCC ONLINE SERVICES
 
BCC offers an online information retrieval service. BCC’s home page, located at www.bccresearch.com, enables readers to:  
  • Examine BCC’s complete catalog of Market Research Reports and place direct orders
  • Subscribe to any of BCC’s many industry newsletters
  • Read announcements of recently published reports and newly launched newsletters
  • Register for BCC’s well-known conferences
  • Request additional information on any BCC product
  • Take advantage of special offers 
DISCLAIMER
 
The information developed in this report is intended to be as reliable as possible at the time of publication and of a professional nature. This information does not constitute managerial, legal, or accounting advice; nor should it serve as a corporate policy guide, laboratory manual, or an endorsement of any product, as much of the information is speculative in nature. The author assumes no responsibility for any loss or damage that might result from reliance on the reported information or its use. 

Table of Contents & Pricing

All reports provided in PDF format. For shared licensing options (5+ Users), please call a representative at (+1) 781-489-7301 or contact us at info@bccresearch.com
Note: Reports are discounted or included with certain Memberships. See Membership Options.
 
CUSTOM RESEARCH

Need a custom data table, graph or complete report? Tell us more.

Contact Us
RELATED REPORTS
Share This Report